Cartesian Therapeutics announced that it has dosed the first patient in a Phase I/IIa multicenter clinical study evaluating Descartes-25, engineered to deliver a combination of synergistically active anti-myeloma therapies directly to tumor microenvironment, in patients with multiple myeloma.
[Cartesian Therapeutics]
7992332
{7992332:BBBBBBBB}
apa
50
1
171111
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
